July 25, 2019 10:05 AM EDTUpdated July 26, 02:38 PM
News Briefing

ICER backs cost-ef­fec­tive­ness of Vas­cepa, Xarel­to; Epizyme's lead drug wins speedy US re­view

Natalie Grover

Reporter

→ Drug cost-ef­fec­tive­ness watch­dog ICER on Wednes­day un­veiled pre­lim­i­nary find­ings from its draft re­port on ad­di­tive car­dio­vas­cu­lar dis­ease ther­a­pies: Amarin’s $AM­RN fish oil pill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times